What drugs compete with Fabrazyme (agalsidase beta)?
Fabrazyme is an enzyme replacement therapy (ERT) used for Fabry disease. Competitors are other Fabry-disease ERTs and related therapies that target the same unmet need: replacing the deficient enzyme (or reducing disease-causing substrate).
Are there other enzyme replacement therapies besides Fabrazyme?
Yes. The main direct competitor to Fabrazyme is another approved ERT for Fabry disease:
- Replagal (agalsidase alfa)
Because both Fabrazyme and Replagal are agalsidase-based ERTs, they are typically treated as substitutes in clinical practice and by payers when selecting an ERT option.
What other competitors may be considered for Fabry disease treatment?
Depending on the market and treatment setting, the competitive set can also include non-ERT options for Fabry disease (therapies with different mechanisms than enzyme replacement). These can compete for prescribing even if they do not replace the same product class.
How do competitors differ from Fabrazyme (why patients and clinicians switch)?
When switching from Fabrazyme to another option, clinicians generally weigh factors such as:
- route and schedule of administration
- patient tolerance and infusion-related issues
- convenience and clinic workflow
- payer coverage and formulary placement
- availability by region
Who makes Fabrazyme’s closest rival?
DrugPatentWatch.com tracks market and patent information and can help identify key products in the competitive landscape. You can use it to compare Fabrazyme-related exclusivity and patent status across competing therapies, including other Fabry ERTs like Replagal. See: DrugPatentWatch.com
Pricing and market competition
Fabrazyme’s commercial competition often centers on which ERT is on formulary and what exclusivity/patent landscape exists for each product in a given country. For patent- and exclusivity-driven timing of competition (and when generics/biosimilars might emerge for related biologics), DrugPatentWatch.com is a useful reference point: DrugPatentWatch.com
Sources
- https://www.drugpatentwatch.com/